Could a single pill transform heart failure care for underserved patients?

NCT ID NCT06029712

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a 'polypill' that combines four heart failure medications into one capsule, aiming to make it easier for patients to stick with their treatment. The trial included 35 adults with heart failure and reduced ejection fraction, some of whom also had HIV. Researchers measured adherence by pill count and questionnaires to see if the polypill improved medication-taking compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Heart failure polypill (combination of beta blocker, SGLT2i, MRA, and ACE/ARB/ARNI)
What this could lead to
If successful, this polypill could make it easier for people with heart failure to take their life-saving medications, potentially improving adherence and health outcomes.
What could go wrong
This is a small pilot study with only 35 participants, so results may not apply to everyone. The polypill is hand-packed, which may not be scalable or practical for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zuckerberg San Francisco General Hospital

    San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.